P-144Pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus: Cause or consequence? Analysis of the prevalence of alterations in glucose metabolism (AGM) in a patients ’ cohort with PDAC

Introduction: Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer (PDAC) after cigarette smoking and obesity. Epidemiological investigations have found that long-term type 2 diabetes mellitus is associated with a 1.5- to 2.0-fold increase in the risk of PDAC. On the other hand, new-onset diabetes may indicate subclinical PDAC, and patients with new-onset diabetes may constitute a population in whom PDAC can be detected early. Use of the antidiabetic drugs, such as metformin, has been associated with reduced risk of PDAC in diabetics and recognized as an antitumor agent with the potential to prevent and treat this cancer. Several ongoing clinical trials are exploring this potential benefit in different settings of PDAC.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research